Trade Neurocrine Biosciences, Inc. - NBIX shares price

1m
5m
15m
30m
1H
4H
1D
1W
Open on web platform

Market info

Min traded quantity:
1
Full name:
Neurocrine Biosciences, Inc.
Currency:
USD
Margin:
5%
Stock exchange:
United States of America
Long position overnight fee
-0.0203%
Short position overnight fee
-0.0102%

Trading hours (UTC)

Mon - Fri:
13:30 - 20:00

NBIX

Neurocrine Biosciences, Inc. discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's lead products include INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; elagolix, a gonadotropin-releasing hormone (GnRH) antagonist that is in Phase III clinical trial for use in women's health; and opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trial that is used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease. It is also developing NBI-74788, which is in Phase II clinical trial that is used for the treatment of congenital adrenal hyperplasia. In addition, the company's research programs comprise VMAT2 Inhibitors for movement disorders, bipolar disorders, and schizophrenia; and G Protein-Coupled Receptors and Ion Channels for epilepsy, essential tremor, pain, dystonia, and other indications. It has collaborations and agreements with AbbVie Inc. to develop and commercialize elagolix and GnRH antagonists for women's and men's health; Mitsubishi Tanabe Pharma Corporation to develop and commercialize INGREZZA for movement disorders; and BIAL Portela & Ca, S.A. to develop and commercialize opicapone for the treatment of human diseases and conditions, including Parkinson's disease. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.
White Paper Declaration

You might be interested in

A world first

Our advanced web platform is the world’s first regulated tokenised assets exchange.

Crypto as collateral

Trade the global financial markets using Bitcoin or Ethereum.

Security as priority

Authorised by the High Technology Park of Belarus, the European blockchain regulator, the safety of your holdings is guaranteed.

Technical indicators

Keep an eye on your positions with over 75 advanced charts, price analysis and price alerts.

Control your capital

Use stop-loss and take-profit orders to keep what you earn.

Use the world’s first regulated tokenised assets exchange to build a diverse investment portfolio with your crypto holdings. Make your deposits in Bitcoin or Ethereum to trade global financial instruments with competitive leverage and tight spreads. Currency.com keeps your holdings secure and accessible at a glance.

VISA MASTERCARD Yandex Money WIRE Faster payments SEPA PCI BTC ETH